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based on Brazilian guidelines for HTA (Vianna, 2007). The study was based on clinical 
data published by AWAD 2007, showing PHS device has lower recurrence rate com-
pared to Polypropylene mesh (0.6% versus 2.7%, p  0.04) in 17 months. The recur-
rence rate was projected to 60 months (PHS 2.1%; Polyprolylene mesh 9.2%) to 
evaluate clinical and economic long-term impact. The average incidence rate of 2% 
for inguinal hernia was based on Brazilian specialist’s opinions. The econom impact 
of recurrence was calculated considering 200.000 patients. Procedure costs, hospital 
stay, devices costs and medical staff fees were obtained from Brazilian public lists 
(CBHMP 4a. ed., Boletim Proahsa and SIMPRO). According to local guidelines, 5% 
of discount rate was adopted. One-way sensitivity analysis was performed to verify 
the robustness of the results. RESULTS: According to the model, 108 patients will 
need reintervention in the Polypropylene mesh group versus 24 in the PHS group in 
17 months, representing 74% on reoperation reduction. In 60 months, 368 patients 
will need reintervention in the Polypropylene group versus 84 in the PHS, 77% reop-
eration reduction. There was a positive impact of recurrence in the PHS group of 
R$ 105,401 for a 17 months period (R$ 100,382 discounted) and R$ 355,821 for a 
60 months period (R$ 292,730 discounted). CONCLUSIONS: Findings suggest PHS 
as a safe and efﬁcient alternative for inguinal hernia repair when compared with 
Polypropylene mesh and can generate resource economy under the payer perspective 
in Brazil.
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OBJECTIVES: Opioid induced constipation (OIC) is an important adverse event in 
the management of patients with chronic pain. The aim of this project was to describe 
the current management (prevention, treatment, complications) and resource use of 
OIC in Belgium (B) and The Netherlands (NL), and to estimate to estimate the associ-
ated cost (societal perspective). METHODS: A 2-round Delphi panel was performed 
in a sample both of 24 general practitioners (GPs) (12 per country). Questions were 
related to current medical practice (medical treatment, tests and imaging, consulta-
tions, hospitalizations, treatment of complications and impact of OIC on work pro-
ductivity). Pain was deﬁned as persisting for at least three months and for which 
opioids were permanently administered. Costs were calculated by multiplying average 
resource use obtained from the Delphi panel with speciﬁc unit costs (ofﬁcial tariffs). 
RESULTS: The cost per day for prevention of OIC (before a ﬁrst episode (primary) 
or to prevent a new episode (secondary)) was respectively a1.33 and a2.13 for Belgium 
and The Netherlands. Respectively 68%/89% of the patients in Belgium/The Nether-
lands received primary laxative-prophylaxis (average duration per 3 months: 47 days 
(B) and 58 days (NL)). Secondary prophylaxis was given in 100% of the patients. The 
cost of a constipation-episode was 130a in Belgium, a102 in The Netherlands. The 
higher cost in Belgium was mainly due to higher cost for tests and treatment. Cost of 
complications (B: 8% of patients, NL: 12%) of OIC ranged in Belgium between a71 
(abdominal pain) and a1386 (rectal prolapse). Cost of complications in The Nether-
lands ranged between a23 (vomiting) and a410 (faecal impaction). Work absenteeism 
due to OIC and related complications resulted in a cost of a42 for Belgium and a128 
for The Netherlands. CONCLUSIONS: Management of OIC has an important eco-
nomic impact both in Belgium and The Netherlands, especially when complications 
occur.
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OBJECTIVES: To compare the cost-effectiveness of iv PPI (80 mg bolus followed by 
8 mg/h infusion for 72 h) in patients considered at risk of gastric or duodenal ulcer 
(peptic ulcer) rebleeding after therapeutic endoscopy. METHODS: A systematic 
review and mixed treatment comparison (WinBUGS) provided estimates of the relative 
risk of peptic ulcer rebleed, repeat endoscopy and emergency surgery with acute iv 
PPI using placebo as a common comparator. A decision analytic model was then used 
to determine the cost per quality adjusted life years (QALYs) gained for iv esomepra-
zole, iv pantoprazole and iv omeprazole. Patients with no rebleed received 28-day 
treatment with the respective oral PPI (esomeprazole 40 mg od, pantoprazole 40 mg 
od or omeprazole 20 mg od). Costs of medical and operative procedures were sourced 
from the National Schedule of Reference Costs (2007/08). Disutilities for repeat 
endoscopy and surgery were estimated from a published study that used time trade 
off interviews in adults with peptic ulcer disease. A 30-day time horizon was used. 
The analysis was conducted from the perspective of the UK National Health Service 
(NHS). Uncertainty was investigated through one way sensitivity analysis and proba-
bilistic Monte Carlo simulation. RESULTS: Intravenous esomeprazole was the pre-
ferred treatment strategy. Probabilistic Monte Carlo simulation indicated that, at a 
threshold of £20,000/QALY, there was a 66% probability that iv esomeprazole was 
the most cost-effective compared to 33% and 1% for iv omeprazole or iv pantopra-
zole, respectively. The NHS would need to adopt a cost-effectiveness threshold in 
excess of £65,000/QALY for iv omeprazole to be considered the most cost-effective 
treatment for this indication. CONCLUSIONS: Based on the current best available 
evidence, iv esomeprazole, the only European licensed iv PPI for the prevention of 
recurrent peptic ulcer bleed after therapeutic endoscopy, is the most cost-effective 
treatment option and represents good value for money for the NHS.
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BACKGROUND: Iron deﬁciency and anaemia (Hb-level      12 g/dl) is common in 
patients with inﬂammatory bowel disease (IBD). First line treatment for correcting 
iron deﬁciency is oral iron. In patients intolerant to oral iron, intravenous (IV) iron 
is recommended. OBJECTIVES: To evaluate incremental costs and effects (ICER) of        
IV iron compared to discontinuation of oral iron, in IBD patients intolerant to oral 
iron. METHODS: A micro-simulation model of the Hb-level and intravenous or oral          
iron treatment was developed using published data, a chart review of IBD patients 
and calibration. QALYs and costs for drug (including administration), transport and 
loss of production due to IV iron administration in an outpatient setting were esti-
mated using a one-year time frame with two relapses causing anaemia. At treatment 
start, patients are in relapse with a Hb-level of 10 g/dl and treated with oral iron. As        
they become intolerant, the model either switches them to IV iron or discontinues 
treatment. Sensitivity analyses were carried out with respect to initial Hb and number 
of relapses per year. RESULTS: In the base case, treatment with IV iron generates a 
QALY gain of 0.0334 at a cost of a1,530, i.e. an ICER of a45,800. A treatment start 
at lower initial Hb-levels generates higher QALY-gains and lower costs per QALY, 
e.g. a35,900 per QALY gained with an initial Hb-level of 9 g/dl. The ICER in patients 
with one relapse per year gain is a61,460, reﬂecting a high initial cost when determin-
ing appropriate iron treatment regimen. CONCLUSIONS: In a health care perspective,     
IV iron compared to oral iron is cost-effective in patients in relapse. In a societal 
 perspective, IV iron is cost-effective provided that 50% of the patients work 
during relapse.
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OBJECTIVES: Adherence to the prescribed treatment regimen is an important factor 
that impacts on the success of therapy in chronic hepatitis C. The aim of this study 
was to develop a cost-effectiveness analysis of a multidisciplinary support program 
(MSP) versus conventional treatment in a group of Hepatitis C (HC) patients. 
METHODS: A total of 278 naïve and mono-infected patients with HC were included 
in the study: 131 in Group 1 (MSP strategy) and 147 in Group 2 (conventional treat-
ment approach). All patients were treated with Peg-IFN-alfa-2a and Ribavirin. The 
MSP not only included hepatologists and nurses, but also, pharmacists, psychologists 
and assistants; additionally uniform patient education, open and ﬂexible visits schedul-
ing, continued evaluation of psychiatric risk and active medication were carried out. 
A decision-tree model was built to estimate the incremental cost-effectiveness ratio 
(ICER) of MSP vs. conventional control. Unitary costs of HC drugs and professionals 
were included. Effectiveness was measured in terms of sustained virological response 
(SVR), adherence was deﬁned as 80% dose administered. RESULTS: For genotypes 
1/4 (G-1/4), adherence was achieved in 92.4% of patients in group 1 and 69.3% in 
group 2 (p  0.0005), for genotypes 2/3 (G-2/3) adherence was achieved in 96.9% 
and 93.2% in groups 1 and 2 respectively (p  0.05). SVR differed in the two groups: 
66.7% in group 1 and 48.9% in group 2 for G-1/4 (p  0.03) and 87.7% and 81.4% 
for G-2/3 (p  0.05) for groups 1 and 2 respectively. Cost per SVR was higher in 
group 2 than in group 1 (a24,079 and a20,197 in G-1/4; a8,351 and a7,723 in G-2/3). 
The ICER was a9,533/SVR in G-1/4 patients and group 1 was dominant over group 
2 in G-2/3 patients. CONCLUSIONS: The MSP could improve the adherence to the 
HC treatment and therefore the virological response, and could be also a cost-effective 
strategy compared with the conventional approach.
PGI11
THE COST EFFECTIVENESS OF INFLIXIMAB IN THE TREATMENT OF 
ACUTE ULCERATIVE COLITIS PATIENTS IN SCOTLAND
Shore E
Schering-Plough, Welwyn Garden City, Herts, England
OBJECTIVES: To estimate the cost effectiveness of inﬂiximab treatment among         
patients with severely active ulcerative colitis (UC) hospitalised with an acute exacer-
bation. METHODS: A decision analytic model was used to simulate the progression          
of hypothetical cohorts of patients with an exacerbation of UC receiving different 
treatment strategies, inﬂiximab, ciclosporin, standard care or surgical intervention. 
For extrapolation beyond the trial period, a Markov model was used. The relative 
risk of disease progression on different treatment alternatives was determined by an 
indirect comparison between clinical trial. The primary outcome was quality adjusted 
life years (QALYs) using EQ-5D estimates. A time horizon of one year was selected 
based on the decision problem and the availability of evidence. Costs and beneﬁts 
